Oncology Stakeholders Offer Niche Recommendations To US FDA, But Who Will Ultimately Get Their Way?
Executive SummaryAdvocates, industry give wish lists for changes to Office of Oncology Excellence, but Commissioner Scott Gottlieb will ultimately determine who gets what.
You may also be interested in...
Brad Thompson says that phone calls used in current informal process help sponsors understand Office of Combination Product’s thinking, and that a formalized process envision in the new draft guidance could make this dialogue more difficult.
In an exclusive interview with Generics Bulletin sister publication the Pink Sheet, the now-permanent OTBB director Sarah Yim discussed her expectations for the future of the US biosimilars market, her learning experience as acting director and upcoming challenges for her office.